Introduction: Dacomitinib was superior to gefitinib in terms of progression-free survival in patients with EGFRmutant lung cancer in a recent ARCHER 1050 trial. However, despite a marked initial response, lung cancers eventually acquire resistance to these inhibitors. This study aimed to elucidate the mechanisms of acquired resistance to dacomitinib in vitro.
Introduction
Targeted therapy with tyrosine kinase inhibitors (TKIs) is a standard treatment for patients with epidermal growth factor receptor gene (EGFR)-mutated lung cancer. The ARCHER 1050 trial demonstrated superiority of dacomitinib, an irreversible second generation (2G) TKI, to reversible first-generation (1G) gefitinib in terms of progression-free survival (PFS). 1 The median PFS times were 14.7 months in the dacomitinib group and 9.2 months in the gefitinib group, with a hazard ratio of 0.59. 1 mechanism of acquired resistance to gefitinib, erlotinib, or afatinib is known to be a secondary EGFR T790M mutation, 2 which can be overcome by osimertinib. 3 However, except for data on bypass tracks and EGFR amplifications, data on the mechanisms of acquired resistance to dacomitinib are limited. [4] [5] [6] To overcome resistance and discuss the best sequence of TKI therapy, it is essential to elucidate the associated resistance mechanisms.
The purpose of this study was to elucidate EGFR secondary mutations as mechanisms of acquired resistance to dacomitinib using in vitro models with or without N-ethyl-N-nitrosourea (ENU) mutagenesis.
Materials and methods

Cell Culture and Reagents
The interleukin-3-dependent murine pro-B-cell line Ba/F3 was provided by RIKEN Bio Resource Center (Tsukuba, Japan). Cells were cultured in Roswell Park Memorial Institute 1640 medium (Wako, Osaka, Japan) with 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO). EGFR TKIs (gefitinib, erlotinib, dacomitinib, and osimertinib) were purchased from Selleck Chemicals (Houston, TX).
Construction of Retroviral Vector-Transduced Cell Lines
EGFR mutations were introduced into Ba/F3 cells by using retroviral vectors as previously described. 7, 8 Briefly, pBABE retroviral vector with the full-length complementary DNA encoding EGFR gene was provided by Addgene (Cambridge, MA). The EGFR Del19 (del E746_A750), L858R, G719A, and L858R plus C797S mutations were generated by using a Prime-STAR Mutagenesis Basal Kit (Takara, Kusatsu, Japan). The constructs were cotransfected with a pVSV-G vector (Clontech, Palo Alto, CA) into gpIRES-293 cells using FuGENE6 transfection reagent (Roche Diagnostics, Basel, Switzerland) to produce viral particles. Infected Ba/F3 cells were cultured in the absence of interleukin-3.
Establishment of Dacomitinib-Resistant Clones
We previously demonstrated that the concentrations for 90% inhibition of Ba/F3 cells transfected with Del19, L858R, or G719A were lower than 6 nM. 7 Considering that the clinically achievable trough concentration (the lowest concentration reached by a drug before the next dose is administered) of dacomitinib was 166 nM in a phase I trial, 9 these three mutations seem to be sensitive to dacomitinib. Therefore, these three cells were used in the present study.
Dacomitinib-resistant clones were rapidly established by ENU (Sigma Aldrich) mutagenesis. 8 After the exposure to 100 mg/mL of ENU for 24 hours, cells were Additionally, a low concentration (20 nM) of dacomitinib was also evaluated to mimic the dose modification in the clinic. When the cells reached confluence, they were regarded as having acquired resistance. In another experiment, Ba/F3 cells expressing Del19 were chronically exposed to increasing concentrations of dacomitinib. The final concentration of dacomitinib was set at 200 nM.
EGFR Mutational Analyses
Total RNA was isolated from resistant cells and then reverse-transcribed into complementary DNA. EGFR exons 18 to 21 were amplified with primers, and Sanger sequencing was performed by using a Genetic Analyzer 3130 or 3500XL (Applied Biosystems, Waltham, MA) as previously reported. 8 
Statistical Analyses
Time to resistance to dacomitinib was defined as the time between the initial date of exposure to dacomitinib and the date on which the cells reached confluence. Timeto-resistance curves according to each EGFR secondary mutation were estimated by the Kaplan-Meier method, and differences were compared by using the log-rank test by JMP, version 8.0.2 (SAS Institute Inc., Cary, NC).
Cell Growth Inhibition Assay
A quantity of 2 Â 10 3 cells were plated and grown for 24 hours. After 72 hours of exposure to EGFR TKIs, Cell Counting Kit-8 reagent (Dojindo Laboratories, Kumamoto, Japan) was added. The absorbance at 450 nm was read with a multiplate reader (Tecan, Mannedorf, Switzerland). The data are expressed as growth percentages relative to that of the DMSO-treated controls.
Results
Secondary EGFR Mutations in DacomitinibResistant Clones
To clarify secondary EGFR mutations as resistance mechanisms and the frequency of these mutations, we generated resistant clones through ENU mutagenesis. In total, 171 resistant clones were obtained (Fig. 1) . T790M mutations accounted for 90% of the secondary mutations (154 of 171). C797S mutations arose in L858R-mutant cells (four of 35) and G719A-mutant cells (12 of 50) in the low-dose (20 nM) setting. One G719A-mutant clone developed C797S even with the high dose of dacomitinib.
Ba/F3 cells expressing EGFR Del19 acquired resistance to 200 nM dacomitinib after 2 months of exposure. T790M was also detected in these resistant cells ( Fig. 2A) .
Sequencing chromatograms of C797S mutations in L858R-mutant clones and their protein structures are shown in Fig. 2B and 2C , respectively.
Association between Drug Exposure Durations and the Type of Secondary EGFR Mutations
To clarify whether the timing of development ofT790M and C797S mutations is different, time to resistance was compared between T790M-and C797S-mutant clones established with 20 nM dacomitinib and ENU mutagenesis. The median times to resistance of L858R-mutant clones that acquired T790M and C797S mutations were both 15 days (p ¼ 0.93). Similarly, the median durations to resistance of G719A-mutant clones that acquired T790M and C797S mutations were both 16 days (p ¼ 0.86) (Fig. 3) .
In Vitro Sensitivities of T790M-or C797S-Mutant Cells to Various EGFR TKIs
To overcome T790M mutations in response to dacomitinib treatment, in vitro sensitivities of Ba/F3 cells with Del19 plus T790M mutations established by chronic exposure to dacomitinib without ENU were determined. Although the concentration that inhibits 50 percent (IC 50 ) of dacomitinib was 483 nM, that of osimertinib was only 2.8 nM (Fig. 4A) .
Subsequently, EGFR L858R plus C797S mutations were retrovirally introduced into Ba/F3 cells to characterize C797S mutation. Cells expressing L858R plus C797S mutations were sensitive to both gefitinib and erlotinib. The IC 50 values of gefitinib and erlotinib were 2.8 and 9.9 nM, respectively. C797S-mutant cells showed moderate resistance to dacomitinib, with an IC 50 of 23.8 nM considering the trough concentration of dacomitinib in plasma (Fig. 4B ).
Discussion
In this study, we demonstrated that dacomitinib directly induced EGFR T790M or C797S secondary mutations in Ba/F3 cells transfected with EGFR Del19, L858R, or G719A mutations, which did not contain de novo resistant T790M or C797S clones. Additionally, the times for the emergence of these two mutations were not significantly different. The T790M-mutant cells were sensitive to osimertinib, whereas the C797S-mutant cells were sensitive to gefitinib or erlotinib.
Our discovery that dacomitinib induced both T790M and C797S seems to be reasonable considering the structure of drugs. 1G and 2G TKIs share a quinazoline core structure, which works for the adenosine triphosphate-competitive binding. On the other hand, 2G and third-generation (3G) TKIs share an acrylamide structure that is capable of forming covalent bond between TKIs and cysteine 797 of EGFR. Therefore, 2G TKI dacomitinib has both reversible and irreversible inhibitory effects. We previously reported that another 2G TKI, afatinib, also induced C797S as a resistance mechanism. 8 Regarding EGFR secondary mutations as resistance mechanisms, Ba/F3 models are useful because these cells transfected with EGFR mutations grow depending on only EGFR signals when they are cultured without interleukin-3. Although ENU artificially influences the emergence of mutations, novel mutations obtained through ENU mutagenesis screening have been detected in clinical samples. The novel L792F mutation that we had discovered as a mechanism of resistance to afatinib 8 has been detected in patient tumors with acquired resistance to osimertinib. 10 This is consistent with our data showing that L792F-mutant cells exhibit weak resistance even to 3G TKIs. To overcome resistant C797S Figure 3 . Time to resistance to 20 nM dacomitinib in Ba/F3 cells with L858R and G719A mutations that acquired T790M or C797S mutation. Time-to-resistance curves according to each EGFR secondary mutation were estimated by the Kaplan-Meier method. Differences were compared between T790M-mutant clones and C797S-mutant clones by using the log-rank test. ENU, N-ethyl-N-nitrosourea. mutations, preclinical data including ours suggest the use of 1G TKIs gefitinib or erlotinib. 8, 11 In patients with acquired resistance to osimertinib, gefitinib monotherapy was shown to successfully shrink T790M-negative/C797S-positive tumor 12 and a combination of gefitinib and osimertinib was effective for the tumor with T790M and in trans C797S mutations. 13 Associations between drug exposure durations and types of resistance mechanisms have been reported. Oxnard et al. reported interesting data indicating that time to treatment failure in response to osimertinib was longer in patients with tumors harboring the T790M mutation even after osimertinib resistance than in patients with loss of EGFR dependency through bypass signaling or histologic transformation.
14 Regarding dacomitinib resistance, we obtained additional data showing that the durations to resistance between C797S-and T790M-mutant clones are similar. Our model might be one of the useful methods to simulate the time course of patients treated with TKIs.
Compared with 1G TKIs, osimertinib significantly prolonged PFS in the FLAURA trial. 15 Osimertinib is undoubtedly one of the best EGFR TKIs in terms of efficacy and toxicity. However, dacomitinib can play an important therapeutic role not only as a first-line agent but also as a second-line agent, and the EGFR L792F mutation, which is known to confer resistance to osimertinib, is sensitive to dacomitinib. 8 Thus, tracking the dynamic onset of secondary mutations and selecting appropriate TKIs on the basis of each secondary mutation can maximize therapeutic benefit for patients.
In conclusion, T790M or C797S secondary mutations can emerge as mechanisms of resistance to dacomitinib in vitro, and the associated acquired resistance can be overcome with 3G or 1G TKIs, respectively. Thus, we have highlighted the importance of analyzing these secondary mutations in clinical samples to overcome resistance. Our data should be confirmed by using patient-derived xenograft models or in clinical samples.
